IGM Biosciences Valuation
| IGMS Stock | USD 10.43 0.97 10.25% |
At this time, the firm appears to be undervalued. IGM Biosciences retains a regular Real Value of $13.23 per share. The prevalent price of the firm is $10.43. Our model calculates the value of IGM Biosciences from examining the firm fundamentals such as return on asset of -0.37, and Return On Equity of -1.32 as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting IGM Biosciences' valuation include:
Price Book 7.1254 | Enterprise Value 389.6 M | Enterprise Value Ebitda (1.99) | Price Sales 212.5468 | Enterprise Value Revenue 133.5165 |
Undervalued
Today
Please note that IGM Biosciences' price fluctuation is slightly risky at this time. Calculation of the real value of IGM Biosciences is based on 3 months time horizon. Increasing IGM Biosciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the IGM stock is determined by what a typical buyer is willing to pay for full or partial control of IGM Biosciences. Since IGM Biosciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of IGM Stock. However, IGM Biosciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 10.43 | Real 13.23 | Target 22.09 | Hype 10.35 |
The intrinsic value of IGM Biosciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence IGM Biosciences' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of IGM Biosciences helps investors to forecast how IGM stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of IGM Biosciences more accurately as focusing exclusively on IGM Biosciences' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use IGM Biosciences' intrinsic value based on its ongoing forecasts of IGM Biosciences' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against IGM Biosciences' closest peers.
IGM Biosciences Cash |
|
IGM Valuation Trend
IGM Biosciences' real value is important for investors to make better decisions and a more accurate overall view of IGM Biosciences' financial worth over time. Using both IGM Biosciences' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
IGM Biosciences Total Value Analysis
IGM Biosciences is currently expected to have valuation of 389.6 M with market capitalization of 620.21 M, debt of 40.51 M, and cash on hands of 469.14 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the IGM Biosciences fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
389.6 M | 620.21 M | 40.51 M | 469.14 M |
IGM Biosciences Investor Information
About 35.0% of the company shares are held by company insiders. The company recorded a loss per share of 3.61. IGM Biosciences had not issued any dividends in recent years. Based on the key indicators related to IGM Biosciences' liquidity, profitability, solvency, and operating efficiency, IGM Biosciences is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December.IGM Biosciences Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. IGM Biosciences has an asset utilization ratio of 0.5 percent. This implies that the Company is making $0.005031 for each dollar of assets. An increasing asset utilization means that IGM Biosciences is more efficient with each dollar of assets it utilizes for everyday operations.IGM Biosciences Ownership Allocation
IGM Biosciences has a total of 34.08 Million outstanding shares. Over half of IGM Biosciences' outstanding shares are owned by outside corporations. These outside corporations are typically referred to as corporate investors that purchase positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.IGM Biosciences Profitability Analysis
The company reported the previous year's revenue of 2.13 M. Net Loss for the year was (246.42 M) with profit before overhead, payroll, taxes, and interest of 1.07 M.About IGM Biosciences Valuation
The stock valuation mechanism determines IGM Biosciences' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of IGM Biosciences based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of IGM Biosciences. We calculate exposure to IGM Biosciences's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of IGM Biosciences's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -6.1 M | -6.5 M | |
| Pretax Profit Margin | (115.37) | (121.14) | |
| Operating Profit Margin | (123.69) | (129.88) | |
| Net Loss | (115.69) | (121.47) | |
| Gross Profit Margin | (2.89) | (3.03) |
IGM Biosciences Growth Indicators
Investing in growth stocks can be very risky. If the company such as IGM Biosciences does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 52.3 M |
IGM Biosciences Current Valuation Indicators
IGM Biosciences' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final IGM Biosciences' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as IGM Biosciences, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use IGM Biosciences' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes IGM Biosciences' worth.Additional Tools for IGM Stock Analysis
When running IGM Biosciences' price analysis, check to measure IGM Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IGM Biosciences is operating at the current time. Most of IGM Biosciences' value examination focuses on studying past and present price action to predict the probability of IGM Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IGM Biosciences' price. Additionally, you may evaluate how the addition of IGM Biosciences to your portfolios can decrease your overall portfolio volatility.